[EN] PYRIDINE AND ISOQUINOLINE DERIVATIVES AS SYK- AND JAK-KINASE INHIBITORS [FR] DÉRIVÉS DE PYRIDINE ET D'ISOQUINOLÉINE EN TANT QU'INHIBITEURS DES SYK- ET JAK-KINASES
Highly potent aminopyridines as Syk kinase inhibitors
摘要:
A novel class of potent Syk inhibitors has been developed from rational design. Highly potent aminopyridine derivatives bearing a 4-trifluoromethyl-2-pyridyl motif and represented by compound 13b IC50: 0.6 nM were identified. Substitution by a 2-pyrazinyl motif and SAR expansion in position 4 of the central core provided diverse potent non-cytotoxic Syk inhibitors showing nanomolar activity inhibiting human mast cell line LAD2 degranulation. (C) 2012 Elsevier Ltd. All rights reserved.
[EN] PYRIDINE AND ISOQUINOLINE DERIVATIVES AS SYK- AND JAK-KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIDINE ET D'ISOQUINOLÉINE EN TANT QU'INHIBITEURS DES SYK- ET JAK-KINASES
申请人:ALMIRALL SA
公开号:WO2012041476A1
公开(公告)日:2012-04-05
The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by inhibition of Syk kinase and/or Janus kinases.
Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
申请人:Almirall, S.A.
公开号:EP2441755A1
公开(公告)日:2012-04-18
The present invention relates to a compound of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by inhibition of Syk kinase and/or Janus kinases.
A novel class of potent Syk inhibitors has been developed from rational design. Highly potent aminopyridine derivatives bearing a 4-trifluoromethyl-2-pyridyl motif and represented by compound 13b IC50: 0.6 nM were identified. Substitution by a 2-pyrazinyl motif and SAR expansion in position 4 of the central core provided diverse potent non-cytotoxic Syk inhibitors showing nanomolar activity inhibiting human mast cell line LAD2 degranulation. (C) 2012 Elsevier Ltd. All rights reserved.